Blueprint Medicines Corp (NASDAQ:BPMC) COO Kate Haviland sold 1,571 shares of Blueprint Medicines stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $95.47, for a total value of $149,983.37. Following the completion of the sale, the chief operating officer now directly owns 17,436 shares in the company, valued at $1,664,614.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Kate Haviland also recently made the following trade(s):

  • On Monday, June 17th, Kate Haviland sold 11,952 shares of Blueprint Medicines stock. The stock was sold at an average price of $96.46, for a total value of $1,152,889.92.

Shares of NASDAQ BPMC opened at $97.75 on Friday. The stock’s 50 day moving average is $91.81. The company has a quick ratio of 6.59, a current ratio of 6.59 and a debt-to-equity ratio of 0.27. Blueprint Medicines Corp has a 1-year low of $44.58 and a 1-year high of $101.91. The company has a market capitalization of $4.80 billion, a PE ratio of -18.14 and a beta of 1.55.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.98) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.83) by ($0.15). Blueprint Medicines had a negative return on equity of 59.26% and a negative net margin of 603.88%. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $1.38 million. During the same period in the previous year, the firm earned ($1.29) earnings per share. The company’s revenue was down 23.2% compared to the same quarter last year. As a group, equities analysts predict that Blueprint Medicines Corp will post -7.76 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC increased its stake in Blueprint Medicines by 5.3% during the first quarter. FMR LLC now owns 6,939,294 shares of the biotechnology company’s stock worth $555,491,000 after acquiring an additional 346,738 shares during the last quarter. OppenheimerFunds Inc. increased its stake in Blueprint Medicines by 0.3% during the first quarter. OppenheimerFunds Inc. now owns 1,710,895 shares of the biotechnology company’s stock worth $136,957,000 after acquiring an additional 5,720 shares during the last quarter. Norges Bank bought a new stake in Blueprint Medicines during the fourth quarter worth approximately $42,705,000. Eagle Asset Management Inc. increased its stake in Blueprint Medicines by 0.3% during the first quarter. Eagle Asset Management Inc. now owns 763,908 shares of the biotechnology company’s stock worth $61,150,000 after acquiring an additional 2,639 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Blueprint Medicines by 6.6% during the fourth quarter. Geode Capital Management LLC now owns 492,662 shares of the biotechnology company’s stock worth $26,559,000 after acquiring an additional 30,499 shares during the last quarter. 97.45% of the stock is currently owned by institutional investors.

Several equities research analysts have recently issued reports on BPMC shares. Goldman Sachs Group raised Lenovo Group from a “neutral” rating to a “buy” rating in a report on Thursday, May 23rd. They noted that the move was a valuation call. Deutsche Bank lifted their target price on eBay from $42.00 to $46.00 and gave the stock a “buy” rating in a report on Thursday. Robert W. Baird started coverage on Blueprint Medicines in a report on Thursday. They issued an “outperform” rating and a $120.00 target price on the stock. Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a report on Monday, June 17th. Finally, Zacks Investment Research cut German American Bancorp. from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $108.13.

About Blueprint Medicines

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Recommended Story: Why does a company issue an IPO?

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.